Fig. 1 | Bone Marrow Transplantation

Fig. 1

From: Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)

Fig. 1

Overall survival and cumulative incidences with estimates at six months after first MSC-FFM administration. a The overall survival (OS) of all patients treated with MSC-FFM. b The cumulative incidence for all patients as to non-relapse mortality (NRM) and relapse mortality (RM) by the underlying disease is displayed. c, d Overall survival and non-relapse mortality related to the age and therapy prior to MSC-FFM administration (e, f). (Colour figure online)

Back to article page